课题基金 / 基金详情

Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease

Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
具有异常糖蛋白特异性的致病性自身抗体:自身免疫性疾病治疗靶点的评估
批准号:
10359090
负责人:
Todd Jason Green
金额:
$51.58万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-03-01 至 2025-02-28

项目摘要

项目成果

Todd Jason Green的其他基金

相似基金

相关文献

中文摘要
翻译
IgA肾病是世界上最常见的肾小球肾炎,可导致终末期肾病。 20%-40%的患者,可能会使预期寿命减少多达10年,因为目前还没有已知的治疗方法或疾病- 具体治疗。大多数IgAN患者,无论年龄和种族,都存在免疫缺陷,导致 产生致病的含有IgA1的免疫复合体,最终沉积在肾脏中诱导 肾损伤。这些肾脏免疫沉淀物可能来源于由IgA1组成的循环免疫复合体 与铰链区缺乏半乳糖的O-糖链(Gd-IgA1)结合Gd-IgA1特异性免疫球蛋白自身抗体。这个 这个项目的长期目标是确定导致致病的潜在机制。 免疫复合体,这样就可以开发针对IgAN的治疗方法。我们的假设是一个分子- IgAN患者Gd-IgA1特异性免疫球蛋白自身抗体的水平特征与原子水平的结合 免疫复合体中自身抗体的特征将极大地促进我们对 免疫球蛋白肾病免疫复合体的形成。这些信息将反过来为开发新的 针对疾病的治疗。在过去的三年里,调查人员的实验室利用 开始对特异性IgAN进行生化、分子、结构和临床研究 自身抗体。我们已经证明,来自IgAN患者的免疫球蛋白自身抗体含有一个序列(氨基酸 在骨架3和重链(VH)的可变部分中的CDR3的交界处的酸), 其中丝氨酸残基是Gd-IgA1结合所必需的。这种丝氨酸残留物来自一种体细胞 高度突变(Ala-≫Ser),而不是来自VH生殖系基因的遗传突变。我们的晶体研究 用IgAN来源的(YCSK)和生殖系回复(YCAK)的重组免疫球蛋白抗体显示 氨基酸序列的这种看似微小的差异对周围的元素产生了变构效应 丝氨酸残基,产生一个与CDR环并列的新表面。这个表面是一个潜在的结合部位。 为部分Gd-IgA1铰链区糖肽,是设计免疫球蛋白自身抗体的潜在靶点 抑制剂。在这项建议中,我们将确定免疫球蛋白在人群和个体水平上的变异性 基于VH/VL序列和Gd-IgA1结合的IgAN中的自身抗体(目标1),确定结构 具有代表性的免疫球蛋白自身抗体的特征和Gd-IgA1识别的分子机制(目标2), 并开发方法来阻断Gd-IgA1的免疫球蛋白自身抗体的结合(目标3)。通过利用我们的 获得生物库临床样本、新患者、新的高通量克隆方法和 特异性Gd-IgA1的免疫球蛋白自身抗体的表达、高分辨结构分析方法和高分辨率 对于抑制剂的吞吐量测试,我们的研究已经进展到了一个阶段,即分子水平的评估 自身抗体将促进我们对导致IgAN疾病的机制的理解。结果是 我们的研究将确定疾病特异性靶点,以防止IgAN病原性免疫复合体的形成。
英文摘要
IgA nephropathy (IgAN), the most common glomerulonephritis worldwide, leads to end-stage renal disease in 20-40% of patients and can reduce life expectancy by up to 10 years, as there is no known cure or disease- specific treatment. Most IgAN patients, regardless of age and ethnicity, have immunologic defects resulting in generation of pathogenic IgA1-containing immune complexes, which ultimately deposit in the kidneys to induce renal injury. These renal immunodeposits likely originate from circulating immune complexes consisting of IgA1 with hinge-region galactose-deficient O-glycans (Gd-IgA1) bound by Gd-IgA1-specific IgG autoantibodies. The long-term goal of this project is to define the underlying mechanisms that lead to the formation of pathogenic immune complexes, so that IgAN-specific treatments can be developed. Our hypothesis is that a molecular- level characterization of Gd-IgA1-specific IgG autoantibodies from IgAN patients coupled with an atomic-level characterization of autoantibodies in immune complexes will significantly advance our understanding of immune-complex formation in IgAN. This information will in-turn provide a basis for development of new disease-specific treatments. Over the past three years, the laboratories of the investigators have utilized biochemical, molecular, structural, and clinical studies to begin characterization of IgAN-specific autoantibodies. We have shown that IgG autoantibodies from patients with IgAN harbor a sequence (amino acids YCSR/K) at the junction of framework 3 and the CDR3 in the variable part of the heavy chain (VH), wherein the serine residue is essential for Gd-IgA1 binding. This serine residue originates from a somatic hypermutation (Ala->Ser) and not from a genetic mutation of a VH germline gene. Our crystallographic studies with an IgAN-derived (YCSK) and a germline-reverted (YCAK) recombinant IgG autoantibody revealed that this seemingly minor difference in the amino-acid sequence had allosteric effects on elements surrounding the serine residue, generating a new surface juxtaposed to the CDR loops. This surface is a potential binding site for part of the Gd-IgA1 hinge-region glycopeptide and is a potential target for the design of IgG autoantibody inhibitors. In this proposal, we will determine the population- and individual-level variability of IgG autoantibodies in IgAN based on VH/VL sequences and Gd-IgA1 binding (Aim 1), determine the structural features of representative IgG autoantibodies and the molecular mechanism of Gd-IgA1 recognition (Aim 2), and develop approaches to block the binding of IgG autoantibodies to Gd-IgA1 (Aim 3). By leveraging our access to biobanked clinical samples, new patients, the new high-throughput approaches for cloning and expression of IgG autoantibodies specific Gd-IgA1, high-resolution methods for structural analyses, and high- throughput testing of inhibitors, our studies have progressed to a stage where molecular-level assessments of the autoantibodies will advance our understanding of the mechanisms that drive IgAN disease. The results of our studies will define disease-specific targets to prevent pathogenic immune-complex formation in IgAN.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
Pathogenic Autoantibodies with Specificity for Aberrant Glycoproteins: Assessment of a Therapeutic Target in an Autoimmune Disease
Transcription and replication in nonsegmented negative-strand RNA viruses
Transcription and replication in nonsegmented negative-strand RNA viruses
海外基金